Bioretec was granted FDA’s Breakthrough Device Designation for its RemeOs Spinal Interbody Cage. RemeOs Spinal Interbody Cages are intended to be used to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine.
Bioretec’s biodegradable RemeOs Spinal Interbody Cage met the strict criteria set for entering the FDA’s Breakthrough Device Designation program. FDA requires a breakthrough technology to provide more effective treatment for life-threatening or irreversibly debilitating conditions or diseases. In addition, breakthrough technology must either represent a completely new form of treatment or offer significant advantages over existing approved or cleared alternatives, including the potential to reduce the need for hospitalization, improve patient’s quality of life, and create long-term clinical benefits, or alternatively represent a form of treatment that is in the best interest of patients. Under the Breakthrough Devices Program, the FDA will enable an ongoing and prioritized interactive discussion between Bioretec and the authorities regarding the commercial access of RemeOs Spinal Interbody Cage implant in the U.S. market.
“This designation gives us another validation of our expertise in creating innovative products for the unmet clinical needs in the orthopedic field. I am enthusiastic about the future prospects and the market opportunities of this product, which is based on the patented hybrid technology,” states Timo Lehtonen, the CEO of Bioretec.
Bioretec was granted FDA’s Breakthrough Device Designation for its RemeOs Spinal Interbody Cage. RemeOs Spinal Interbody Cages are intended to be used to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine.
Bioretec’s biodegradable RemeOs Spinal Interbody Cage met the strict criteria set for entering...
Bioretec was granted FDA’s Breakthrough Device Designation for its RemeOs Spinal Interbody Cage. RemeOs Spinal Interbody Cages are intended to be used to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine.
Bioretec’s biodegradable RemeOs Spinal Interbody Cage met the strict criteria set for entering the FDA’s Breakthrough Device Designation program. FDA requires a breakthrough technology to provide more effective treatment for life-threatening or irreversibly debilitating conditions or diseases. In addition, breakthrough technology must either represent a completely new form of treatment or offer significant advantages over existing approved or cleared alternatives, including the potential to reduce the need for hospitalization, improve patient’s quality of life, and create long-term clinical benefits, or alternatively represent a form of treatment that is in the best interest of patients. Under the Breakthrough Devices Program, the FDA will enable an ongoing and prioritized interactive discussion between Bioretec and the authorities regarding the commercial access of RemeOs Spinal Interbody Cage implant in the U.S. market.
“This designation gives us another validation of our expertise in creating innovative products for the unmet clinical needs in the orthopedic field. I am enthusiastic about the future prospects and the market opportunities of this product, which is based on the patented hybrid technology,” states Timo Lehtonen, the CEO of Bioretec.
Copy to clipboard 
